I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19

I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19

I-Mab to Initiate the Development of TJM2 for Treating Cytokine Release Syndrome Associated with COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post